Costo efectividad de insulina lispro protamina (NPL) vs. combinación de insulina NPH + insulina rápida

Villarreal Ríos, E; Montoya Hernández, MA; Vargas Daza, ER; Cervantes Becerra, RG; Galicia Rodríguez, L; Martínez González, L.
O.F.I.L ; 30(3): 221-226, 2020. tab
Artigo em Espanhol | IBECS (Espanha) | ID: ibc-200164

Documentos relacionados

  1. [Current concept of insulin therapy intensification, and the role of human regular insulin and rapid-acting insulin analogs in insulin treatment].
  2. Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis.
  3. What is the value of faster acting prandial insulin? Focus on ultra rapid lispro.
  4. Fields of application of continuous subcutaneous insulin infusion in the treatment of diabetes and implications in the use of rapid-acting insulin analogues.
  5. Photoacoustic imaging reveals mechanisms of rapid-acting insulin formulations dynamics at the injection site.
  6. Analysis of the local dynamics of human insulin and a rapid-acting insulin analog by hydrogen/deuterium exchange mass spectrometry.
  7. Rapid-Acting and Human Insulins: Hexamer Dissociation Kinetics upon Dilution of the Pharmaceutical Formulation.
  8. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics.
  9. Insulin biosimilars: the impact on rapid-acting analogue-based therapy.
  10. Treatment of diabetic ketoacidosis with subcutaneous insulin lispro: a review of the current evidence from clinical studies.